Theme: Advanced Regulatory Compliance in Pharmacovigilance operations and innovations

Pharmacovigilance 2017

Pharmacovigilance 2017

Conference Series LLC solicts your gracious presence at the upcoming 9th International Conference and Exhibition on Pharmacovigilance scheduled to happen during July 17-19, 2017 in Munich, Germany focussing on the advancements in emerging research and technologies in pharmacovigilance, clinical trials and risk management.

Join Hands with Global Influencers and Experts from USA (America), Europe, Middle East , Asia Pacific and Africa at Pharmacovigilance Conferences and Drug Safety Conferences happening from July 17-19, 2017 in Munich, Germany

The field of Pharmacovigilance is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. 9th International Conference and Exhibition on Pharmacovigilance  emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. Main theme of  9th International Conference and Exhibition on Pharmacovigilance is “Advanced Regulatory Compliance in Pharmacovigilance operations and innovations”.

Track 1: Pre-Clinical and Clinical Trials:

Preclinic ​al trials involves the assessment of  of potential therapeutic interventions in cells and animals. Clinical trials is the research conducted on patients using of patient data, disease mechanisms, therapeutic interventions and epidemiology. Clinical data is a key feature transforming basic research into medical care. Pre-Clinical and Clinical Trials involve human subjects to intervention to study the cause-and-effect relationship between a medical intervention and a health outcome. The perfect outcome of clinical trials is minimize risks, enhance benefits, and optimal use of an intervention of therapeutic drugs.

 Track 2 : Adverse Drug Reactions:

Adverse Drug Reaction (ADR) is the contrary reactions caused by taking a medication. Many Adverse Drug Reactions represent an overwhelming side effects of the drug's therapeutic effects.  Adverse Drug Reactions of Drugs can be studied by reporting the mechanism of adverse drug reactions and maintaining the drug safety systems. This track is about expected and un-expected drug reactions and its reporting. Manufacturers, Professionals, and Consumers can report Post marketing reports on adverse effects.

Track 3 : Clinical Trials on Various Disorders:

Clinical Trials on various diseases include Clinical Trials in long chronic diseases like AIDS, Benign and Malignant Tumours,Cardiovascular diseases, Diabetes, Clinical Trials on Monoclonal and Polyclonal Antibodies, Neurological, Physiological and Psychological Disorders,

Track 4: Pharmacovigilance and Risk Management :

Pharmacovigilance and Risk Management ia set of pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to medicinal and therapeutic products including the assessment of the effectiveness of their clinical interventions.and combination therapies. Drug industry need to promote companies in pharmacovigilance practice to use information technology and to Review softwares used in pharmacovigilance and clinical trials. Monitoring unlicensed, off labels and orphan drugs is major task in risk management. Many experts from different pharmacovigilance CRO's , pharmacovigilance service providers and industrial delegates are participating in this conference to share their knowledge and discuss about the new updates.

Track 5: Drug Safety

Drug Safety is the pharmacological science ensuring safety and related to the collection, detection, assessment, monitoring, and prevention of adverse side effects with pharmaceutical products. In this track,we discuss Drug safety and its applications in various fields such as Softwares, Training etc.
 

Track 6: Good Pharmacovigilance Practice:

The role of Good Pharmacovigilance Practice and Pharmacoepidemiology in Risk Management is mainly to  increase the probability of beneficial effects of a drug in a population than the probability of adverse effects and to maintain the Good Reporting Practices by avoiding the major problems in risk management. Also it is important to concentrate on Signal investigation by gathering the information on new or unknown drug effects that is potentially caused by a medicine and that finally should lead to ensuring safety. The pharmacovigilance and clinical trials services providing companies should have the Pharmacovigilance certification .

Track 7:  Data Quality Management and Analysis

 Good data quality management in pharmacovigilance can be relied only on information gathered from the collection of individual case safety reports and other pharmacoepidemiological data. Quality management consists of quality planning, quality control, quality assurance and quality improvements. The pharmacovigilance data processing cycle starts with data collection and, in computerised systems, data entry; the next step is data storage and maintenance; followed by data selection, retrieval and manipulation. The resulting data output is analysed and assessed. Finally, conclusions are drawn and decisions made. The quality of a pharmacovigilance data system can be defined as a measure of excellence or a state of being free from defects, deficiencies and significant variations and the  data quality management includes all the activities that organizations use to direct, control and coordinate the quality of data.

Track 8: Pharmacovigilance Significance & Scope:

Concept of Pharmacovigilance and its Significance enhances the impact of pharmacovigilance on patient welfare and public health and to know what is pharmacovigilance. This track gives a brief discussion on Pharmacovigilance role in healthcare system. Pharmacovigilance legislation gives an outlook on the rules and laws to follow in Pharmacovigilance practice. The Role of pharma industries in the improvement of pharmacovigilance system is very crucial to maintain the safety data, Detection and Evaluation of drug safety signals through manual and medical devices reporting. Pharmacovigilance scope also deals as Ecopharmacovigilance (EPV), pharmacoenvironmentology and pharmacovigilance in herbal medicines

Track 9 : Diversity in Industrial Clinical Trials and Clinical Research

The clinical trial industry is constantly evolving with diversified clinical research technologies and new clinical studies are being launched at an ever-growing pace. Clinical trials have always been a vital part of the medicine development process, as they provide clinical data on the best ways for treating pathological disorders and diseases. The importance of diversity in industrial clinical trials and clinical research is to ensure that industrial clinical trials are doing due diligence and being as strategic as possible in their results.This diversity makes us to better understand the unmet medical needs of patients.

Track 10: Clinical Research and Statistics:

In Clinical Research, Statistics plays a prominent role in regulatory submissions. Statistical analysis of  Pharmacovigilance can be achieved by several guidelines mainly ICH guidelines. Adverse Drug Reactions reports can also be considered for the regulatory submission.

Track 11 : Case Report in Clinical Trials:

Case Report in Clinical Trials plays a key role in Clinical Research. Case reports may be on unexpected association between diseases, disorders or symptoms. An unexpected event in the course of observing, treating a patient,possibilities of  pathogenesis of a disease or an adverse effect.Unique or rare salient features of a disease or therapeutic approaches or a notable variation of the anatomical structures.

Track 12 : Pharmacokinetics and Pharmacodynamics:

Drugs may undergo, Pharmacokinetics and Pharmacodynamics and toxicity testing through animal testing. The phenomena of drug absorption, distribution, metabolism, and excretion and pharmacokinetic principles enhances the safety and efficacy of  therapeutic management of pharmaceutical drugs in an individual patient drug therapy. Pharmacodynamic Interactions, Drug and substance abuse, Drug-drug interactions and clinical drug intervention data allows research scientist estimate a safe starting dose of the drug for clinical trials in humans.

Track 13: PV Data Base Management:

There is an advantage in centralising all safety data, clinical data, analysis and reporting with one provider. Pharmacovigilance Software tool provides comprehensive analysis of adverse events arising from the use of Pharmaceutical products (Medicinal Product, Medical Device, Vaccines, Non-Drug Therapy and Veterinary Medicinal Product). The drug safety database allows the risk- benefit analysis of medicinal products taking into account new and emerging information, in the context of cumulative information. Pharmacovigilance since beginning has been a compliance driven activity, wherein your regulatory compliance determines company’s risk assessment scores. A drug safety database offers scheduling of alerts for expedited cases, follow-up cases and PSUR/PADER reports submission to meet regulatory timeline compliance.

Track 14 : PV Consulting’s and Business opportunity:

Due to the changing resources necessary to fulfil the regulatory requirements, some companies also choose to outsource or out task regulatory affairs to external service providers. Regulatory Affairs department is constantly evolving and growing and is the one which is least impacted during the Acquisition and Merger, and also during recession..The global pharmacovigilance market and Business opportunity bwas valued at USD 2,408.0 million in 2013 and is expected to grow at a CAGR of 12.6% during the forecast period. Phase III clinical trials market was the second largest and was valued at over USD 750.0 million in 2013.

Track 15 : Regulatory Affairs :

Regulatory Affairs for clinical trials is the major part in the clinical trials approaches. Every clinical trial must be analysed according to the Regulatory Affairs Guidelines. There are several Regulatory Affairs departments depending upon the countries within evergrowing pace of companies. Global Harmonization in standards has led to consistent approach in regulatory submissions and hence its review.

Track 16 : Growth strategies in Pharma:

Strategies for Growth in Pharma Environment track mainly focused in Strategic development towards FDA approval and Post market product Surveillances. The updates and advances in Pharmacovigilance Regulation system are discussed under Advances in Changing Pharmacovigilance Regulation System track.

Track 17 Pharmacy Practices and its Challenges:

Pharmacy practice is the field of pharmacy which involves developing the professional roles of pharmacists. It includes Disease-state management, Clinical drug interventions, Pharmacy professional development and pharmaceutical care, pharmaceutical compounding and health psychology, patient care, drug abuse prevention, prevention of drug interactions or minimisation of adverse events and drug incompatibility and community pharmacy.

Conference Series LLC is organizing splendorous Pharmaceutical conferences welcomes you to attend the 9th International Conference and Exhibition on Pharmacovigilance  to be held during July 17-19, 2017 in Vienna, Austria. It focuses on the advancements in Pharmacovigilance, Risk Management, Drug Safety.

The field of Pharmacovigilance is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. 9th International Conference and Exhibition on Pharmacovigilance  emphasizes on how the importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors. 

Why to attend???

With members from around the world focused on learning about Pharmacovigilance and its advances; this is your best opportunity to reach the largest assemblage of participants from the Pharmacovigilance community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive named recognition at this 3-days event. World-Renowned Speakers, the most recent techniques, developments, and the newest updates in Pharmacovigilance are Hallmarks of this Conference.

Target Audience:

  • Pharmacovigilance Students, Scientists
  • Pharmacovigilance Researchers
  • Pharmacovigilance Faculty
  • Medical Colleges
  • Pharmacovigilance Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Software Developing Companies
  • Manufacturing Medical Devices Companies
  • Data Management Companies
Pharmacovigilance 2016

Pharmacovigilance-2016 Report

 Pharmaovigilance 2016 past Conference Report

Thanks to all of our wonderful Speakers, Conference Attendees and Sponsors; Pharmacovigilance 2016 Conference was our best ever!

The “7th International Conference and Exhibition on Pharmacovigilance”, hosted by the Conferenceseries LLC was held on August 22-24, 2016 in Fleming Hotel Wien-Westbahnhof
Neubaugürtel, 26-28,1070 Vienna, Austria. Generous response and active participation was received from the scientists, researchers and leaders from clinical, government organizations, students who made this conference as one of the most successful and productive events in 2016.

With the support and guidance of Organizing Committee Members and Editorial Board Members and astonishing presentations of all participants this prominent summit became more impressive.

Conferenceseries LLC would like to convey a great appreciation to Keynote speakers Eugenia Hong, Nathan Cummins and Alexey Skripkin.

Honourable guests and Keynote Speakers supported this event with sustainable excitement for grand success of this prominent conference. Also it is our pleasure to announce next 9th International Conference and Exhibition on Pharmacovigilance which will be held during July 17-19, 2017 in Munich, Germany with the theme “Advanced Regulatory Compliance in Pharmacovigilance operations and innovations”.

We hope your favorable support will make next conference also one more grand success.

For more details about Pharmacovigilance 2017 visit

http://pharmacovigilance.pharmaceuticalconferences.com/

 


Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date July 17-19, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
pharmacovigilance@omicsgroup.com
Sponsors / Exhibiting / Advertising.
General Queries.

View Proceedings of Previous Conferences

pharmacovigilance-and-pharmaceutical-industry-2016-proceedings
pharamacovigilance-and-clinical-trials-2015-proceedings
pharmacovigilance-and-clinical-trials-2014-proceedings
pharmacovigilance-clinical-trials-2013-proceedings
Authorization Policy

By registering for the conference you grant permission to Conferenceseries Ltd to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.